Occudo Quantitative Strategies’s Oramed Pharmaceuticals ORMP Stock Holding History

Occudo Quantitative Strategies’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,515	Closed	-$247K	–	1118
2022 Q4	$247K	Sell	20,515 -1,389	-6%	-$10.8K	0.03%	717
2022 Q3	$142K	Sell	21,904 -78,312	-78%	-$634K	0.01%	1006
2022 Q2	$459K	Buy	100,216 +45,983	+85%	+$246K	0.04%	646
2022 Q1	$469K	Buy	54,233 +8,209	+18%	+$84.1K	0.04%	674
2021 Q4	$657K	Buy	46,024 +1,542	+3%	+$32.2K	0.06%	514
2021 Q3	$978K	Buy	44,482 +16,736	+60%	+$285K	0.12%	292
2021 Q2	$371K	Buy	27,746 +5,547	+25%	+$63.4K	0.06%	516
2021 Q1	$226K	Buy	+22,199	New	+$182K	0.05%	587

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SIGI

Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Occudo Quantitative Strategies's ORMP Position: Q1 2023 in Review

Occudo Quantitative Strategies sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 20,515 shares — an estimated $247K sold.

Occudo Quantitative Strategies first reported a position in ORMP in Q1 2021 and held it in 8 quarters. The position peaked at $978K in Q3 2021. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

Occudo Quantitative Strategies reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Occudo Quantitative Strategies sold 20,515 Oramed Pharmaceuticals shares in Q1 2023, an estimated $247K.
Occudo Quantitative Strategies first reported a position in Oramed Pharmaceuticals in Q1 2021 and held it in 8 quarters.
Occudo Quantitative Strategies's Oramed Pharmaceuticals position peaked at $978K in Q3 2021.
61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2023, filed 15 May 2023.